PharmaCyte Biotech’s Diabetes Treatment to Be Presented at Austrodrugs 2015
June 12 2015 - 9:25AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today reported that the company’s
diabetes treatment and the research program of its international
Diabetes Consortium will be presented at the Austrodrugs 2015
conference to be held on June 12 in Vienna, Austria. The
Austrodrugs conference is one of the leading disease treatment
development meetings in central Europe.
Dr. Eva-Maria Brandtner, Director of Diabetes
Program Development for PharmaCyte Biotech, has been invited to
deliver the presentation, titled “Encapsulated Insulin-producing
Cells for Treatment of Diabetes,” to the Austrodrugs 2015
conference. Dr. Brandtner is currently Head of the Bioencapsulation
Unit at the Vorarlberg Institute for Vascular Investigation and
Treatment (VIVIT) in Austria. Prior to joining the team at the
VIVIT, Dr. Brandtner was with Austrianova Singapore where she
directed the initial studies with Melligen insulin-producing cells,
both non-encapsulated and encapsulated, using the Cell-in-a-Box®
cellulose-based live-cell encapsulation technology.
Melligen cells, developed by Prof. Dr. Ann
Simpson and her colleagues at the University of Technology Sydney
from a human liver cell line, have been shown to be able to produce
insulin as the level of blood sugar rises in their surroundings. In
her presentation, Dr. Brandtner will discuss the Diabetes
Consortium’s ongoing studies with Melligen cells. These cells, when
encapsulated using the Cell-in-a-Box® technology, form the basis
for PharmaCyte Biotech’s treatment for insulin-dependent diabetes
currently under development.
PharmaCyte Biotech’s Chief Executive Officer,
Kenneth L. Waggoner, commented, “We are very pleased that Dr.
Brandtner has been invited to make this important presentation at
the prestigious Austrodrugs conference in Vienna and would like to
thank the organizing committee of the conference for inviting her
to do so. Because of her previous experience with Melligen cells
and her current role in our international Diabetes Consortium, Dr.
Brandtner is the ideal person to give this presentation. We believe
Dr. Brandtner’s presentation will give visibility to our
international Diabetes Consortium’s efforts to develop a treatment
for insulin-dependent diabetes - a serious life-threatening disease
that affects millions around the world.”
The Austrodrugs conference is organized by the
Research Center for Molecular Medicine (CeMM) in Austria. CeMM is
the international independent and interdisciplinary research
institute of the Austrian Academy of Sciences. The Austrian Academy
of Sciences, founded in 1847, is the leading organization promoting
non-university academic research in Austria. The CeMM, located on
the campus of the Medical University of Vienna, is committed to
advancing the understanding of human diseases through basic and
biomedical research.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company
focused on developing and preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based live
cell encapsulation technology known as Cell-in-a-Box®. This unique
and patented technology will be used as a platform upon which
treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
PharmaCyte Biotech's treatment for pancreatic cancer involves low
doses of the well-known anticancer prodrug ifosfamide, together
with encapsulated live cells, which convert ifosfamide into its
active or "cancer-killing" form. These capsules are placed as close
to the cancerous tumor as possible to enable the delivery of the
highest levels of the cancer-killing drug at the source of the
cancer. This "targeted chemotherapy" has proven remarkably
effective in past clinical trials.
PharmaCyte Biotech is also working towards
improving the quality of life for patients with advanced pancreatic
cancer and on treatments for other types of solid cancerous tumors.
In addition, PharmaCyte Biotech is developing treatments for cancer
based upon chemical constituents of the Cannabis plant, known as
cannabinoids. In doing so, PharmaCyte Biotech is examining ways to
exploit the benefits of Cell-in-a-Box® technology in optimizing the
anticancer effectiveness of cannabinoids, while minimizing or
outright eliminating the debilitating side effects usually
associated with cancer treatments. This provides PharmaCyte Biotech
the rare opportunity to develop “green” approaches to fighting
deadly diseases, such as cancer of the pancreas, brain and breast,
which affect hundreds of thousands of individuals worldwide every
year.
Safe Harbor
This press release may contain forward-looking statements
regarding PharmaCyte Biotech and its future events and results that
involve inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to PharmaCyte Biotech or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of
PharmaCyte Biotech, could cause actual results to differ materially
from those set forth in the forward-looking statements. They
include PharmaCyte's ability to continue as a going concern, delays
or unsuccessful results in preclinical and clinical trials, flaws
or defects regarding its product candidates, changes in relevant
legislation or regulatory requirements, uncertainty of protection
of PharmaCyte Biotech’s intellectual property and PharmaCyte
Biotech’s continued ability to raise capital. PharmaCyte Biotech
does not assume any obligation to update any of these
forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com